FAK-IN-28
Product Specifications
Target
ROS, FAK, Apoptosis, Caspase
Related Pathways
Immunology/Inflammation, Proteases/Proteasome, Cytoskeletal Signaling, Apoptosis, Tyrosine Kinase/Adaptors, Angiogenesis
Bioactivity
FAK-IN-28 is an orally active FAK inhibitor with an IC50 of 0.4 nM. It exhibits both antiproliferative and antimetastatic effects. FAK-IN-28 induces apoptosis by triggering caspase-3-dependent pathways through increased ROS levels. This compound effectively inhibits tumor growth without causing weight loss or hepatorenal toxicity. FAK-IN-28 is suitable for research on FAK-driven malignancies, including colon cancer, cervical cancer, triple-negative breast cancer, and melanoma.
Shipping Conditions
Ice Packs
Storage Temperature
-20°C
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog